Adoptive cell transfer (ACT) of tumor-infiltrating lymphocytes (TILs) that target neoantigens can cause tumor regression in certain patients with metastatic epithelial cancer. However, identifying and utilizing neoantigen-reactive T cells for treatment remains challenging, and it is unclear if current detection methods miss clinically significant neoantigen reactivities. To address this, scientists explored whether enriching T cells expressing PD-1 and/or activation markers, followed by microwell culturing to prevent the overgrowth of nonreactive T cells, could improve the detection of neoantigen-reactive TILs.
This liner peptide is suggested: MTEYKLVVVGAVGVGKSALTIQLI